-
Research and Reports in Nuclear Medicine
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Leading role of 18F-FDG-PET imaging in early diagnosis of Alzheimer’s disease: an overview
Review
(1578) Views (259) Full article downloads
Authors: Cason E, Treglia G, Fagioli G
Published Date June 2011
Volume 2011:1 Pages 11 - 19
DOI: http://dx.doi.org/10.2147/RRNM.S16142
Ernesto Cason1, Giorgio Treglia2, Giorgio Fagioli11Unit of Nuclear Medicine, Maggiore Hospital of Bologna, Bologna, Italy; 2Institute of Nuclear Medicine, Catholic University of the Sacred Heart, Rome, Italy
Abstract: Early detection of Alzheimer’s disease (AD) is important to reveal preclinical pathological alterations, to monitor disease progression, and to evaluate response to therapy. The study of cerebral glucose metabolism through 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) plays a leading role in early detection of AD because the decrease of cerebral glucose metabolism largely precedes the onset of AD symptoms. This technique demonstrated high sensitivity in early diagnosis of AD, allowing a qualitative and quantitative estimate of cerebral glucose metabolism. Furthermore FDG-PET imaging may help to discriminate the subjects of a high-risk population (like patients with mild cognitive impairment) who more probably will develop AD: an early stage of AD generally shows hypometabolism of medial temporal lobes and parietotemporal posterior cortices; other cerebral cortices are later involved. The combination of FDG-PET with other biomarkers, such as genotype, cerebrospinal fluid markers, and amyloid plaque imaging, may increase the preclinical diagnostic accuracy and offer promising approaches to assess individual prognosis in AD patients.
Keywords: positron emission tomography, dementia, neuroimaging, Alzheimer’s disease, 18F-FDG
Other articles by Dr Giorgio Treglia
Readers of this article also read:
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Health literacy and health seeking behavior among older men in a middle-income nation
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Anesthesiologists’ perception of patients’ anxiety under regional anesthesia
Everolimus-eluting stents: update on current clinical studies
-
Call For Submissions
Submit Original Research Article, Review, Case Report, or Rapid Communication in Research and Reports in Nuclear Medicine
- Imaging of peripheral vascular disease
- Capillary telangiectasia mimicking an active inflammatory MS-lesion in repetitive cMRIs
- Comparison of a new PillCam™ SB2 video capsule versus the standard PillCam™ SB for detection of small bowel disease
- F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET)-positive parotid incidentaloma: Prevalence and clinical significance




